Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Biomarker base™ Introduction


Published on

Published in: Business
  • "9th International Conference on Biomarker” welcomes all the attendees, speakers, sponsor’s and other research expertise from all over the world which is going to be held during October 26 -28, 2017 in Osaka, Japan. We are very much honoured to invite you all to exchange and share your views and experience on the Biomarkers Congress 2017. Oncology & Cancer has evolved into one of the most dynamic specialties in medicine. Biomarkers Congress 2017, in the hands of clinical investigators, provide a dynamic and powerful approach to understanding the spectrum of diseases with obvious applications in analytic epidemiology, biomarkers and clinical research in disease prevention, diagnosis, and disease management. Cancer biomarkers have the additional potential to identify individuals susceptible to disease. For more details:
    Are you sure you want to  Yes  No
    Your message goes here

Biomarker base™ Introduction

  1. 1. Unified Data for Actionable Biomarkers
  2. 2. What Is BiomarkerBase? • A manually curated database that aggregates information from publicly available sources that describe the clinical use of biomarkers. • Provides access to biomarkers that can’t be found through searches in public sources. • Links biomarker information together by target, disease, drug, therapeutic area, and company. 2
  3. 3. - IVD Tests cleared or approved by FDA since the end of 2002 that utilize one or more biomarkers. - Drugs, all FDA-approved, that include a biomarker in the label. - Clinical Trials, phase 3 and 4, initiated since the end of 2011, which include “marker” in the record. Phase 2 trials by Nov ‘13. - Publications describing clinical studies that include biomarkers from the sources above. Current Datasets Biomarker Definition: A nucleic acid, peptide or hormone that is potentially useful for diagnosis, prognosis, or companion diagnosis. 3
  4. 4. Public sources of biomarker information lack connectivity and have severe querying limitations. 4
  5. 5. Query limitation #1: Some of the most critical information can’t even be searched. X 5
  6. 6. Query limitation #1: Some of the most critical information can’t even be searched. 6 X
  7. 7. Query limitation #2: Nomenclature isn’t standardized. Search Term Studies Returned ca 125 153 ca-125 140 mucin-16 138 mucin 16 138 MUC16 0 7
  8. 8. 8
  9. 9. BiomarkerBase Difference Manually Curated ComprehensiveClinically Focused 9
  10. 10. Who Uses BiomarkerBase? Diagnostic Companies Product development; business development; marketing Drug Companies Clinical trial planning; partnering; test selection Life Science Companies Product development; business development; marketing Research Institutions Licensing 10
  11. 11. Subscription Pricing Single User • $1,000 / year • Access for one individual Multi User • $2,500 / year • Unlimited users at a single site within one company or institution • Multi-site licenses are also available at discounted pricing. 11
  12. 12. Amplion Research Inc. 1011 SW Emkay Drive, Suite 200 Bend, Oregon 97702 USA +1.503.389.1157 Contact Information 12